Echinocandins

Mechanism of Action - The Glucan Wall-Breakers

• Non-competitively inhibit the enzyme β-(1,3)-D-glucan synthase.

• This blocks the synthesis of the polysaccharide $$(1→3)-β-D-glucan$$, a critical component of the fungal cell wall.
• Leads to loss of cell wall integrity, osmotic instability, and ultimately, cell lysis.

⭐ A key clinical distinction: Echinocandins are fungicidal against most Candida species but only fungistatic against Aspergillus species.

📌 The name Echinocandin helps remember they target glucan synthesis.

Spectrum & Clinical Uses - Candida's Kryptonite

• Primary Targets:

  • Excellent fungicidal activity against most Candida spp., including azole-resistant C. glabrata & C. krusei.
  • Fungistatic activity against Aspergillus spp.

• Key Gaps in Coverage (No Activity):

  • Cryptococcus neoformans
  • Zygomycetes (e.g., Mucor, Rhizopus)
  • Dimorphic fungi (e.g., Histoplasma capsulatum)

• Clinical Applications:

  • First-line for invasive candidiasis & candidemia, especially in moderate-to-severe illness.
  • Refractory esophageal candidiasis.
  • Second-line therapy for invasive aspergillosis (often in combination).
  • Empiric therapy for suspected fungal infections in febrile neutropenia.

⭐ Exam Favorite: Echinocandins are highly effective against Candida biofilms, making them a superior choice for catheter-related bloodstream infections.

Pharmacokinetics & Resistance - The Body & The Battle

• Pharmacokinetics (ADME):
  • Administration: IV infusion only; negligible oral absorption.
  • Distribution: High plasma protein binding (>97%). Excellent tissue penetration (liver, spleen, lung) but poor penetration into CNS, urine, and eyes.
  • Metabolism: Slow, non-CYP-mediated degradation via hydrolysis and N-acetylation.
  • Excretion: Primarily eliminated in feces; minimal renal clearance.

⭐ Exam Favorite: Echinocandins do not require dose adjustment for renal insufficiency and have very few drug-drug interactions via the CYP450 system. This is a major clinical advantage in complex, polymedicated patients, unlike azoles.

• Resistance Development:
  • Primary mechanism is target site modification through acquired point mutations in the $FKS1$ or $FKS2$ genes.
  • These mutations alter the catalytic Fks1p subunit of the β-(1,3)-D-glucan synthase enzyme, reducing its binding affinity for echinocandins.

High‑Yield Points - ⚡ Biggest Takeaways

• Echinocandins inhibit β-(1,3)-D-glucan synthase, disrupting fungal cell wall synthesis.
• They are the first-line treatment for invasive candidiasis and candidemia, especially in critically ill patients.
• The spectrum covers Candida and Aspergillus but notably lacks activity against Cryptococcus and Mucorales.
• All drugs in this class are administered IV only and end with the suffix "-fungin".
• Generally well-tolerated, with potential for histamine release and infusion-related reactions.